These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 19472560)

  • 21. Risk management of drug products and the U.S. Food and Drug Administration: evolution and context.
    Leiderman DB
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S9-S13. PubMed ID: 19307069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Opioid risk management: understanding FDA mandated risk evaluation and mitigation strategies (REMS).
    Sloan PA
    J Opioid Manag; 2009; 5(3):131-3. PubMed ID: 19662921
    [No Abstract]   [Full Text] [Related]  

  • 23. In brief: propoxyphene toxicity.
    Med Lett Drugs Ther; 2010 Sep; 52(1346):69. PubMed ID: 20814401
    [No Abstract]   [Full Text] [Related]  

  • 24. Perspectives. New twist on guideline dissemination stirs professional debate, gets slap from FDA.
    Newman L
    Med Health; 1999 Feb; 53(8):suppl 1-4. PubMed ID: 10345551
    [No Abstract]   [Full Text] [Related]  

  • 25. Twenty five years of poison center experience with propoxyphene overdoses the FDA could not find.
    Hayes BD; Anderson BD
    Clin Toxicol (Phila); 2009 Nov; 47(9):905-6. PubMed ID: 19814605
    [No Abstract]   [Full Text] [Related]  

  • 26. Oncology nurses at all levels need to know about REMS.
    Haas ML
    ONS Connect; 2010 Mar; 25(3):23. PubMed ID: 20344892
    [No Abstract]   [Full Text] [Related]  

  • 27. Petition targets painkiller marketing in effort to curb overdose deaths.
    Kuehn BM
    JAMA; 2012 Sep; 308(12):1194-6. PubMed ID: 23011691
    [No Abstract]   [Full Text] [Related]  

  • 28. Painkiller crackdown.
    Kalb C
    Newsweek; 2001 May; 137(20):38. PubMed ID: 11373803
    [No Abstract]   [Full Text] [Related]  

  • 29. Adequate controls for new drugs: good manufacturing practice and the 1938 federal Food, Drug, and Cosmetic Act.
    Cooper DE
    Pharm Hist; 2002; 44(1):12-23. PubMed ID: 12068915
    [No Abstract]   [Full Text] [Related]  

  • 30. Extended-release/long-acting opioid REMS may fill the need for prescribers' appropriate use education.
    Nicholson SC; Evanyo K; Salinas GD; Roepke N; Burton BS; Susalka D
    J Opioid Manag; 2012; 8(4):212-6. PubMed ID: 22941848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.
    Epstein RA
    Yale J Health Policy Law Ethics; 2005; 5(2):741-70. PubMed ID: 16052898
    [No Abstract]   [Full Text] [Related]  

  • 32. Pain treatment, drug diversion, and the casualties of war.
    Burgess F
    Pain Med; 2006; 7(6):474-5. PubMed ID: 17112360
    [No Abstract]   [Full Text] [Related]  

  • 33. International Conference on Harmonisation; guidance on Q9 Quality Risk Management; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jun; 71(106):32105-6. PubMed ID: 16795933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug approval process and FDA.
    Schmidt AM
    N Y State J Med; 1976 Nov; 76(12):2039-42. PubMed ID: 1069200
    [No Abstract]   [Full Text] [Related]  

  • 35. FDA committee: More restrictions needed on hydrocodone combination products.
    Kuehn BM
    JAMA; 2013 Mar; 309(9):862. PubMed ID: 23462764
    [No Abstract]   [Full Text] [Related]  

  • 36. Letter: FDA and the drug industry.
    Pitesky I
    Ann Allergy; 1974 Mar; 32(3):178. PubMed ID: 4405952
    [No Abstract]   [Full Text] [Related]  

  • 37. The danger of imperfect regulation: OxyContin use in the United States and Canada.
    Lexchin J; Kohler JC
    Int J Risk Saf Med; 2011; 23(4):233-40. PubMed ID: 22156088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA to propose hydrocodone reclassification.
    J Calif Dent Assoc; 2014 Jan; 42(1):10. PubMed ID: 25080676
    [No Abstract]   [Full Text] [Related]  

  • 39. Statement on intractable pain treatment acts.
    American Alliance of Cancer Pain Initiatives
    J Pain Palliat Care Pharmacother; 2004; 18(2):93-8. PubMed ID: 15257980
    [No Abstract]   [Full Text] [Related]  

  • 40. FDA "reform"?
    Miller HI
    Science; 1998 Jan; 279(5348):158-9. PubMed ID: 9446215
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.